As CD44 supports both chronic inflammation and cancer progression in many (but not all) experimental models and human diseases, CD44 targeting, e.g., by antibody, was successfully documented in many preclinical studies, such as collagen-induced arthritis (CIA) (11). This evidence concerns the gene CD44 and cancer.